Insights
Search Results
Client Highlights
10.01.26
Wilson Sonsini Advises SpyGlass Pharma on Acquisition of Advanced Vision Science
On October 1, 2026, SpyGlass Pharma, a late-stage biopharmaceutical company dedicated to transforming the treatment paradigm for patients living with chronic eye conditions, announced the acquisition of all outstanding shares of Advanced Vision Science (AVS), an ophthalmic medical device company and manufacturer of intraocular lenses (IOLs) and lens materials, for approximately $13 million dollars in cash. This acquisition secures scalable commercial IOL manufacturing capacity for SpyGlass Pharma for its Phase 3 lead product candidate (the BIM-IOL System) and accelerates pathway to adding premium lens options into its IOL-based drug delivery system. Wilson Sonsini Goodrich & Rosati advised SpyGlass Pharma on the transaction.
Client Highlights
9.21.26
Firm Advises CoVet on Acquisition by IDEXX
On September 16, 2026, IDEXX Laboratories, Inc., a global leader in pet healthcare innovation, announced the acquisition of CoVetAI Inc. (CoVet), a leading and rapidly growing provider of AI-native ambient listening and clinical workflow software for veterinary practices. The financial terms of the transaction were not disclosed. Wilson Sonsini Goodrich & Rosati advised CoVet on the transaction.
CoVet helps veterinary teams automatically capture and organize information across the patient care journey, from consultation to treatment planning and client follow-up, reducing documentation burden and saving clinicians’ time. The acquisition expands the value of IDEXX’s software, diagnostics, and AI offerings by making information more accessible, actionable, and connected across the practice. CoVet will be integrated into the IDEXX software ecosystem, which will continue to support other ambient scribe solutions and third-party integrations. CoVet will also continue to integrate with non-IDEXX practice management systems.
The Wilson Sonsini team that advised CoVet on the transaction included:
CoVet helps veterinary teams automatically capture and organize information across the patient care journey, from consultation to treatment planning and client follow-up, reducing documentation burden and saving clinicians’ time. The acquisition expands the value of IDEXX’s software, diagnostics, and AI offerings by making information more accessible, actionable, and connected across the practice. CoVet will be integrated into the IDEXX software ecosystem, which will continue to support other ambient scribe solutions and third-party integrations. CoVet will also continue to integrate with non-IDEXX practice management systems.
The Wilson Sonsini team that advised CoVet on the transaction included:
Client Highlights
9.18.26
Wilson Sonsini Advises Superhuman on Acquisition of Fathom
On September 14, 2026, Superhuman, an AI productivity platform bringing AI to wherever people work, announced its acquisition of Fathom, an AI meeting partner trusted by hundreds of thousands of companies to capture, search, and act on what happens in meetings. Wilson Sonsini Goodrich & Rosati advised Superhuman on the transaction.
Client Highlights
9.10.26
Wilson Sonsini Advises Copart on Acquisition of ACV
On September 10, 2026, Copart, Inc., a global leader in online vehicle auctions, and ACV, a leading digital automotive marketplace and data services partner for dealers and commercial clients, announced a definitive agreement in which Copart will acquire all outstanding shares of ACV common stock, valued at approximately $1.9 billion. Wilson Sonsini Goodrich & Rosati advised Copart on the transaction.
Client Highlights
9.01.26
Firm Advises PMV Pharmaceuticals on Oversubscribed $50 Million Public Offering
On August 31, 2026, PMV Pharmaceuticals, a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, announced the pricing of an underwritten public offering consisting of 22,055,000 shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase an aggregate of up to 19,900,000 shares of its common stock, as well as accompanying warrants to purchase an aggregate of 41,955,000 shares of common stock. The combined public offering price of each share of common stock and accompanying warrant is $1.21. The gross proceeds from the offering, before deducting underwriting discounts, commissions, offering expenses, and any exercise of the warrants, are expected to be approximately $50.8 million. Wilson Sonsini Goodrich & Rosati advised PMV Pharma on the transaction.
Client Highlights
8.20.26
Wilson Sonsini Advises Homeward Health on Acquisition by Cityblock Health
On August 20, 2026, Cityblock Health announced a definitive agreement to acquire Homeward Health in an all-stock transaction. Wilson Sonsini Goodrich & Rosati advised Homeward Health on the transaction.
Client Highlights
8.17.26
Firm Advises Gravis Robotics on $200 Million Series A
On August 17, 2026, Gravis Robotics, a company retrofitting construction machines with autonomous technology, announced their Series A financing, with SoftBank investing $200 million in the company. The funding is the largest Series A in construction robotics history and will be used to scale autonomous machinery, bringing physical artificial intelligence (AI) directly to construction sites and embedding autonomous systems into heavy machinery fleets. Wilson Sonsini Goodrich & Rosati advised Gravis on the transaction.
Client Highlights
8.06.26
Wilson Sonsini Advises Cylinder Health on $105 Million Acquisition by Hinge Health
On August 4, 2026, Hinge Health, a digital healthcare company, announced that it has signed a definitive agreement to acquire Cylinder Health, a leader in virtual-first digestive healthcare, for $105 million in cash consideration. Wilson Sonsini Goodrich & Rosati advised Cylinder Health on the transaction.
Client Highlights
6.11.26
Wilson Sonsini Advises Adyen on $335 Million Acquisition of Orb
On June 11, 2026, Adyen N.V. (AMS: ADYEN), a global financial technology platform, announced it has entered into a definitive agreement to acquire enterprise billing platform Orb for $335 million. Upon closing, Orb will become an indirect, wholly owned subsidiary managed under an incubator model. The strategic intent is to eventually create a unified infrastructure experience for merchants across billing and payments.
Client Highlights
5.14.26
Wilson Sonsini Advises Insider One on Acquisition of Bluecore
On May 13, 2026, Insider One, a leading agentic customer engagement platform, announced its acquisition of Bluecore, a leading retail marketing technology platform serving more than 400 U.S. enterprise brands. Terms of the transaction have not been disclosed. Wilson Sonsini Goodrich & Rosati advised Insider One on the transaction.
Client Highlights
3.13.26
Wilson Sonsini Advises Taggstar on Acquisition by Syndigo
On March 10, 2026, Syndigo, a global leader in product experience management, announced it has acquired Taggstar, a leading AI-powered conversion rate optimization platform for digital commerce. The acquisition expands Syndigo’s product experience cloud by incorporating social proof messaging, attribute messaging and dynamic badging. Terms of the transaction have not been disclosed. Wilson Sonsini Goodrich & Rosati advised Taggstar on the transaction.